尿激酶联合法舒地尔治疗超急性期脑梗死的观察

被引：4

作者：

邓可 ^{[1
,2
]}

机构：

[1] 湖南师范大学附属岳阳医院

[2] 岳阳市二人民医院神经内科

来源：

临床荟萃 | 2013年 / 28卷 / 05期

关键词：

脑梗死; 尿纤溶酶原激活物; 血栓溶解疗法; 法舒地尔; 心房颤动;

D O I：

暂无

中图分类号：

R743.33 [脑栓塞];

学科分类号：

1002 ;

摘要：

目的观察尿激酶联合法舒地尔治疗急性期脑梗死的疗效。方法将91例超急性脑梗死患者分成两组。溶栓组除用抗血小板聚集、扩张血管以及对症治疗以外,用尿激酶100万U加入生理盐水100ml静脉泵输注溶栓治疗1次,后连用14天盐酸法舒地尔30mg加入生理盐水250ml静脉滴注,每天1次。常规组仅用抗血小板聚集、扩张血管以及对症治疗,比较两组入院时及治疗7天后神经功能缺损评分(NIHSS)和临床疗效。结果在入院时NIHSS评分溶栓组明显高于常规组,分别为13分vs 7.5分,治疗7天后溶栓治疗组NIHSS与常规治疗组差异无统计学意义,NIHSS评分4分vs 5分(P>0.05),但溶栓组的显效率高于常规组,58.3%(28/48)vs 4.7%(2/43)(P<0.01)。Logistic回归分析显示患者存在心房颤动病史(OR=0.205,95%CI=0.048～0.867)、入院时血糖值高(OR=0.770,95%CI=0.611～0.971)是导致脑梗死溶栓不成功的危险因素。结论尿激酶联合法舒地尔治疗超急性期脑梗死疗效显著,无明显不良反应。有心房颤动及溶栓前血糖值影响溶栓结局。

引用

页码：512 / 514

页数：3

共 16 条

[1] Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage [J].

Satoh, S ;

Utsunomiya, T ;

Tsurui, K ;

Kobayashi, T ;

Ikegaki, I ;

Sasaki, Y ;

Asano, T .

LIFE SCIENCES, 2001, 69 (12) :1441-1453

[2] Rho/Rho-kinase mediated signaling in physiology and pathophysiology [J].

Wettschureck, N ;

Offermanns, S .

JOURNAL OF MOLECULAR MEDICINE-JMM, 2002, 80 (10) :629-638

[3]

Management of acute is-chemic stroke:current status of pharmacological and mechnicalendovascular methods. Williams M,Patil S,Toledo EGet al. Netrol Res . 2009

[4]

Translational stroke research of the combination of thrombolysis andantioxidant therapy. Amaro S. Chamorro Stroke . 2011

[5]

Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage. Satoh S,Utsunomiya T,Tsurui K et al. Life Sciences . 2001

[6]

Therapeutic results of intra-arterial thrombolysis after full-dose intravenous tissueplasminogen activator administration. Yoo DS,Won YD,Huh PW,et al. American Journal of Neuroradiology . 2010

[7]

Impact of atrial fibril-lation on outcome in thrombolyzed patients with stroke:evi-dence from the Virtual International Stroke Trials Archive (VISTA). Frank B,Fulton R,Weimar C,et al. Stroke . 2012

[8]

Thrombolysis isassociated with consistent functional improvement acrossbaseline stroke severity:a comparison of outcomes in patientsfrom the Virtual International Stroke Trials Archive (VISTA). Mishra NK,Lyden P,Grotta JC,et al. Stroke . 2010

[9]

Using recombinant tissueplasminogen activator to treat acute ischemic stroke in China:analysis of the results from the Chinese National StrokeRegistry (CNSR). Wang Y,Liao X,Zhao X,et al. Stroke . 2011

[10]

Carotid plaqueexulcerated. Rucka D,Lubanda JC,KaretováD,et al. Casopis Lekaru Ceskych . 2011

← 1 2 →